ClinicalTrials.gg
CompletedNCT06785454Updated Aug 21, 2026

A Study to Assess the Efficacy and Safety of Lorundrostat in Participants With Obstructive Sleep Apnea and Hypertension

A Phase 2 interventional study of Lorundrostat and Placebo in Obstructive Sleep Apnea and Hypertension, sponsored by Mineralys Therapeutics Inc.. Completed at 27 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-21.

Sponsored by Mineralys Therapeutics Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 753 studies in Sleep Apnea, Obstructive with a site in United States — 126 open to participants now, 160 under way, 9 of them phase 3. Sleep Apnea, Obstructive · United States.

Enrollment
299th of 594
48 · median 49
Started
2025
with 32 others
Phase 2
53 of 753
8 open now
Registered
689th of 753
by date

Among the 753 studies in Sleep Apnea, Obstructive with a site in United States, this one is the 299th largest by enrollment of the 594 interventional ones that give a count, is one of 33 that started in 2025, is one of 53 in phase 2, and was the 689th registered.

Sleep Apnea, Obstructive

2,243 studies on the registry are indexed under Sleep Apnea, Obstructive; 475 are open to participants now.

Browse Sleep Apnea, Obstructive studies →

Open to participants now

126 of the 753 studies in Sleep Apnea, Obstructive with a site in United States are open now. Recruiting first, the newest first:

121 more — sign in →

All 126 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Sleep Apnea, Obstructive studies recruiting now, 146 (47%) set no upper age limit and 124 (40%) stop at 75 or younger; 52 take children under 18; 65 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 753 studies in Sleep Apnea, Obstructive with a site in United States, or all of them as a file.
02

Study summary

The primary purpose of the study is to assess the effect of lorundrostat taken orally (po) once a day on the Apnea-Hypopnea Index (AHI) in participants with moderate to severe obstructive sleep apnea (OSA) and hypertension.

Read the detailed description

The study is a randomized, double-blind (DB), placebo controlled, crossover study. A 4-week screening period is followed by two DB 4-week treatment periods separated by a 2-week washout period. Participants must be 18 to 75 years old with moderate to severe OSA, hypertension and meet all applicable eligibility criteria. Participants who are medically prescribed and deemed compliant with positive airway pressure (PAP) therapy for greater than or equal to (>=) 4 hours per night (Continuous PAP [CPAP], or automatic PAP [autoPAP]) and for at least 3 months prior to the study enrollment are eligible for the study. Participants on PAP therapy should comply with PAP therapy for the duration of the study. Participants who are not currently on PAP therapy and not anticipated to start PAP for the duration of the study, are also eligible for the study.

03

Conditions studied

  • Obstructive Sleep Apnea
  • Hypertension

Keywords

  • Blood Pressure
  • Hypertension
  • Hypertensive
  • Sleep Apnea
  • Obstructive Sleep Apnea
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. (BMI) ≥ 27 kilograms per meter square (kg/m\^2)
  2. Previously diagnosed with moderate-to-severe OSA
  3. AHI ≥15 events per hour (/hr) prior to Randomization
  4. AOBP SBP of ≥130 and less than or equal to (≤) 180 millimeter of mercury (mmHg) and AOBP diastolic blood pressure (DBP) ≥60 and ≤110 mmHg
  5. Participants on CPAP or PAP therapy are eligible provided they are on PAP for ≥4 hours per night (documented) and for at least 3 months prior to the study enrollment (documented)
  6. Participants not currently on PAP therapy, and not anticipated to start PAP for the duration of the study
  7. Fertile male and female participants of , and their partners, must agree to use protocol-defined methods of highly effective from the Screening Visit until 28 days after the last dose of study drug

Exclusion criteria

Exclusion Criteria:

  1. Type 2 diabetes mellitus (T2DM) with a glycosylated () greater than (>) 9 percent (%) (>74.9 millimoles per mol [mmol/mol]) at the Screening Visit or history of diabetic ketoacidosis in the 6 months prior to the Screening Visit
  2. Participants on a glucagon-like peptide-1 (GLP-1) agonist.
  3. Any surgery for sleep apnea or major ear, nose or throat surgery, including tonsillectomy and adenoidectomy within 3 months prior to Screening, or planned during participation in the study or within 1 month of the last study visit.
  4. Have diagnosis of central or mixed sleep apnea with % of mixed or central apneas/hypopneas ≥50%, or diagnosis of Cheyne Stokes Respiration
  5. Diagnosis of Obesity Hypoventilation Syndrome or daytime hypercapnia
  6. Use of bilevel positive airway pressure (BiPAP) therapy.
  7. less than (\<) 45 milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2) at Screening using serum creatinine or cystatin-C
  8. History of medical, behavioral, or psychiatric disorder, other than OSA, that is associated with insomnia or excessive sleepiness
  9. Diagnosed with Class C
  10. Participants who regularly use caffeine stimulants or participants who are unwilling to reduce intake to 300 mg per day (approximately 3 cups of coffee), for a period of at least 3 days prior to the Screening visit or a sleep study
  11. Treatment with MRAs and/or epithelial sodium channel (ENaC) inhibitors within 1 month of the Screening Visit
  12. Requirement for nocturnal use of supplemental oxygen
  13. Women who are pregnant, plan to become pregnant, or are breastfeeding
  14. Unstable or currently symptomatic cardiovascular disease or hospitalization in the 6 months prior to Screening
  15. Previously diagnosed, recurrent orthostatic hypotension
  16. Current night-shift worker or anticipated to become a night-shift worker for 3 days continuously during the duration of the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Care provider)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Sequence 1: Lorundrostat then Placebo

    Drug: Lorundrostat · Drug: Placebo

  • Experimental
    Sequence 2: Placebo then Lorundrostat

    Drug: Lorundrostat · Drug: Placebo

Interventions

  • Lorundrostat tablet.

  • DrugPlacebo

    Lorundrostat matching placebo tablet.

06

What researchers measure

Primary outcomes

  1. Placebo-adjusted Change From Baseline in AHI at Week 4

    Time frame: Baseline, Week 4

Secondary outcomes

  1. Placebo-adjusted Change From Baseline in Nighttime Average Systolic Blood Pressure (SBP) at Week 4

    Time frame: Baseline, Week 4

  2. Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) SBP at Week 4

    Time frame: Baseline, Week 4

  3. Placebo-adjusted Change From Baseline in Functional Outcomes of Sleep Questionnaire-10 (FOSQ-10) at Week 4

    Time frame: Baseline, Week 4

  4. Placebo-adjusted Change From Baseline in Epworth Sleepiness Scale (ESS) at Week 4

    Time frame: Baseline, Week 4

  5. Placebo-adjusted Change From Baseline in Patient-Reported Outcomes Measurement Information System - Sleep Disturbance (PROMIS-SD) at Week 4

    Time frame: Baseline, Week 4

  6. Placebo-adjusted Change From Baseline in PROMIS Sleep-Related Impairment (SRI) at Week 4

    Time frame: Baseline, Week 4

07

Study locations

27 sites
  • The University of Alabama
    Tuscaloosa, Alabama 35401, United States
  • Chandler Clinical Trials
    Chandler, Arizona 85224, United States
  • Preferred Research Partners Inc.
    Little Rock, Arkansas 72211, United States
  • Orange County Research Institute
    Anaheim, California 92801, United States
  • The Neurology Center of Southern California - Profound Research, LLC
    Carlsbad, California 92011, United States
  • Probe Clinical Research Corporation
    Riverside, California 92501, United States
  • Research Carolina Elite
    Denver, Colorado 28037, United States
  • Nouvelle Clinical Research
    Cutler Bay, Florida 33189, United States
  • Arrow Clinical Trials
    Daytona Beach, Florida 32117, United States
  • PharmaDev Clinical Research Institute, LLC
    Miami, Florida 33176, United States
  • CNS Healthcare - Orlando (Clinical Neuroscience Solutions)
    Orlando, Florida 32801, United States
  • NeuroTrials Research Inc
    Atlanta, Georgia 30328, United States
  • Centricity Research Rincon Pulmonology
    Rincon, Georgia 31326, United States
  • Chicago Research Center Inc
    Chicago, Illinois 60634, United States
  • Centennial Medical Group
    Columbia, Maryland 21045, United States
  • Velocity Clinical Research, Rockville
    Rockville, Maryland 20854, United States
  • Henry Ford Health System/Henry Ford Medical Center - Columbus
    Novi, Michigan 48377, United States
  • Revive Research Institute, Inc
    Southfield, Michigan 48075, United States
  • Healthcare Research Network
    Hazelwood, Missouri 63042, United States
  • Clayton Sleep Institute
    St Louis, Missouri 63123, United States
  • Patient First MD
    Middletown, New Jersey 07748, United States
  • CTI Clinical Research Center
    Cincinnati, Ohio 45212, United States
  • Northwest Research Center
    Portland, Oregon 97202, United States
  • CNS Healthcare - Memphis (Clinical Neuroscience Solutions - Memphis)
    Memphis, Tennessee 38119, United States
  • Huntsville Research Institute LLC
    Huntsville, Texas 77340, United States
  • Sleep Therapy Research Center
    San Antonio, Texas 78229, United States
  • University of Washington
    Seattle, Washington 98104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2025 to primary completion in Dec 2025, 9 months.

Of 47 phase 2 interventional studies under Sleep Apnea, Obstructive, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 46. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2025
First posted
Jan 21, 2025
StartActual
Feb 28, 2025
Primary completionActual
Dec 17, 2025
CompletionActual
Dec 29, 2025
Results delay requested
Aug 17, 2026
Last update
Aug 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06785454
Lead sponsor
Mineralys Therapeutics Inc.
Responsible party
Sponsor
First posted
Jan 21, 2025
Start date
Feb 28, 2025
Primary completion
Dec 17, 2025
Completion
Dec 29, 2025
Last update
Aug 21, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lorundrostat

Start the discussion